vs
Protalix BioTherapeutics, Inc.（PLX）与SuperCom Ltd（SPCB）财务数据对比。点击上方公司名可切换其他公司
SuperCom Ltd的季度营收约是Protalix BioTherapeutics, Inc.的1.6倍（$14.2M vs $9.1M），SuperCom Ltd净利率更高（37.5% vs -60.3%，领先97.8%），SuperCom Ltd同比增速更快（-1.5% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-3.6M）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
Super.com是一家总部位于美国旧金山的科技公司，由侯赛因·法扎勒和施亨利联合创立。该公司主营金融服务业务，具体涵盖会员奖励计划以及旅行预订等相关服务，在出行与消费金融领域深耕发展。
PLX vs SPCB — 直观对比
营收规模更大
SPCB
是对方的1.6倍
$9.1M
营收增速更快
SPCB
高出48.5%
-49.9%
净利率更高
SPCB
高出97.8%
-60.3%
自由现金流更多
PLX
多$5.2M
$-3.6M
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $14.2M |
| 净利润 | $-5.5M | $5.3M |
| 毛利率 | 49.4% | 61.2% |
| 营业利润率 | -51.1% | 16.3% |
| 净利率 | -60.3% | 37.5% |
| 营收同比 | -49.9% | -1.5% |
| 净利润同比 | -184.8% | 79.5% |
| 每股收益（稀释后） | $-0.06 | $1.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXSPCB
| Q4 25 | $9.1M | — | ||
| Q3 25 | $17.9M | — | ||
| Q2 25 | $15.7M | $14.2M | ||
| Q1 25 | $10.1M | — | ||
| Q4 24 | $18.2M | — | ||
| Q3 24 | $18.0M | — | ||
| Q2 24 | $13.5M | $14.4M | ||
| Q4 23 | $10.5M | — |
净利润PLXSPCB
| Q4 25 | $-5.5M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $164.0K | $5.3M | ||
| Q1 25 | $-3.6M | — | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $-2.2M | $3.0M | ||
| Q4 23 | $-6.0M | — |
毛利率PLXSPCB
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | 61.2% | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | 52.3% | ||
| Q4 23 | 15.5% | — |
营业利润率PLXSPCB
| Q4 25 | -51.1% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | 7.5% | 16.3% | ||
| Q1 25 | -41.0% | — | ||
| Q4 24 | 39.6% | — | ||
| Q3 24 | 22.2% | — | ||
| Q2 24 | -18.0% | 7.7% | ||
| Q4 23 | -53.5% | — |
净利率PLXSPCB
| Q4 25 | -60.3% | — | ||
| Q3 25 | 13.2% | — | ||
| Q2 25 | 1.0% | 37.5% | ||
| Q1 25 | -35.8% | — | ||
| Q4 24 | 35.6% | — | ||
| Q3 24 | 18.0% | — | ||
| Q2 24 | -16.4% | 20.6% | ||
| Q4 23 | -57.6% | — |
每股收益（稀释后）PLXSPCB
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $0.00 | $1.32 | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $0.03 | — | ||
| Q2 24 | $-0.03 | $1.19 | ||
| Q4 23 | $-0.03 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $15.0M |
| 总债务越低越好 | — | $23.6M |
| 股东权益账面价值 | $48.2M | $37.3M |
| 总资产 | $82.3M | $65.5M |
| 负债/权益比越低杠杆越低 | — | 0.63× |
8季度趋势，按日历期对齐
现金及短期投资PLXSPCB
| Q4 25 | $14.7M | — | ||
| Q3 25 | $13.6M | — | ||
| Q2 25 | $17.9M | $15.0M | ||
| Q1 25 | $19.5M | — | ||
| Q4 24 | $19.8M | — | ||
| Q3 24 | $27.4M | — | ||
| Q2 24 | $23.4M | $5.7M | ||
| Q4 23 | $23.6M | — |
总债务PLXSPCB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $23.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $29.2M | ||
| Q4 23 | — | — |
股东权益PLXSPCB
| Q4 25 | $48.2M | — | ||
| Q3 25 | $52.9M | — | ||
| Q2 25 | $49.9M | $37.3M | ||
| Q1 25 | $45.2M | — | ||
| Q4 24 | $43.2M | — | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $28.6M | $13.8M | ||
| Q4 23 | $33.6M | — |
总资产PLXSPCB
| Q4 25 | $82.3M | — | ||
| Q3 25 | $82.3M | — | ||
| Q2 25 | $78.5M | $65.5M | ||
| Q1 25 | $73.9M | — | ||
| Q4 24 | $73.4M | — | ||
| Q3 24 | $61.6M | — | ||
| Q2 24 | $91.5M | $49.6M | ||
| Q4 23 | $84.4M | — |
负债/权益比PLXSPCB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.11× | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $-2.2M |
| 自由现金流经营现金流 - 资本支出 | $1.6M | $-3.6M |
| 自由现金流率自由现金流/营收 | 17.8% | -25.3% |
| 资本支出强度资本支出/营收 | 4.4% | 10.0% |
| 现金转化率经营现金流/净利润 | — | -0.41× |
| 过去12个月自由现金流最近4个季度 | $-13.6M | $-14.0M |
8季度趋势，按日历期对齐
经营现金流PLXSPCB
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-3.7M | — | ||
| Q2 25 | $-5.2M | $-2.2M | ||
| Q1 25 | $-5.1M | — | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $4.1M | — | ||
| Q2 24 | $-3.6M | $-950.0K | ||
| Q4 23 | $3.6M | — |
自由现金流PLXSPCB
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-4.2M | — | ||
| Q2 25 | $-5.7M | $-3.6M | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-3.8M | $-1.6M | ||
| Q4 23 | $3.3M | — |
自由现金流率PLXSPCB
| Q4 25 | 17.8% | — | ||
| Q3 25 | -23.7% | — | ||
| Q2 25 | -36.2% | -25.3% | ||
| Q1 25 | -53.0% | — | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | -28.1% | -10.8% | ||
| Q4 23 | 31.9% | — |
资本支出强度PLXSPCB
| Q4 25 | 4.4% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 2.8% | 10.0% | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.3% | 4.2% | ||
| Q4 23 | 2.4% | — |
现金转化率PLXSPCB
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | -0.41× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | -0.32× | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
SPCB
暂无分部数据
